129 results on '"Loman, Laura"'
Search Results
2. Limited Health Literacy and Its Associated Health Outcomes Among Adults With at Least 2 Atopic Diseases
3. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
4. The association between wet work and hand eczema in the Dutch general population: Application of a job exposure matrix to the lifelines cohort study.
5. A genome‐wide association study of hand eczema identifies locus 20q13.33 and reveals genetic overlap with atopic dermatitis.
6. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry
7. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
8. Hand eczema‐related presenteeism and sickness absence: A cross‐sectional population‐based study
9. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
10. Dupilumab in daily practice for the treatment of Pediatric Atopic Dermatitis: 16-week clinical and biomarker results from the BioDay registry
11. Health literacy in adult patients with atopic dermatitis: a cross-sectional study
12. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis
13. Validity, reliability, responsiveness, and interpretability of the Recap of atopic eczema (RECAP) questionnaire
14. Chronisches Handekzem in Europa: Erfassung von Patientenerfahrungen und -perspektiven (CHEPEP) anhand von qualitativen Interviews.
15. A broad vision on hand eczema:pathogenesis, epidemiology and patient care
16. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
17. Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire
18. Which outcomes should be measured in hand eczema trials? Results from patient interviews and an expert survey
19. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
20. European Surveillance System on Contact Allergies (ESSCA)
21. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
22. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
23. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
24. ESDR284 - A genome-wide association study of hand eczema in the Dutch general population
25. 33552 Prevalence and severity of atopic dermatitis and hand eczema, and associated lifestyle factors in the Dutch general population
26. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis
27. Lifestyle factors and hand eczema: a systematic review
28. Association between moderate to severe atopic dermatitis and lifestyle factors in the Dutch general population
29. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
30. Impact of the COVID-19 pandemic on adults with moderate-to-severe atopic dermatitis in the Dutch general population
31. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry
32. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry
33. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
34. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry
35. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
36. Lifestyle factors and hand eczema: A systematic review and meta‐analysis of observational studies
37. Exposure and work‐related factors in subjects with hand eczema: Data from a cross‐sectional questionnaire within the Lifelines Cohort Study
38. Baricitinib treatment of severe chronic hand eczema: Two case reports
39. Patients' perspectives on quality of care for chronic hand eczema: A qualitative study
40. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study
41. Hand eczema and lifestyle factors in the D utch general population: Evidence for smoking, chronic stress, and obesity
42. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis.
43. ESDR114 - Insight into the pathogenesis of vesicular and hyperkeratotic hand eczema
44. European Surveillance System on Contact Allergies ( ESSCA ): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis
45. European Surveillance System on Contact Allergies ( ESSCA ): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis
46. 42622 Association between severity of atopic dermatitis, mental disorders and loneliness in adults in the Dutch general population
47. Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab
48. Hyperkeratotic hand eczema: Eczema or not?
49. Hand eczema and lifestyle factors in the Dutch general population: Evidence for smoking, chronic stress, and obesity.
50. Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.